HomeENGLISH MAGAZINEGenetic nephropathy in children: KIDney gene tells why he gets "on steroids"

Genetic nephropathy in children: KIDney gene tells why he gets “on steroids”

Childhood nephrotic syndrome is the most common chronic kidney disease affecting children; in Japan it occurs at a yearly rate of 6.49 children out of every 100,000 (approximately 1,000 cases in Japan). Nephrotic syndrome causes excessive amounts of protein to be passed in the urine, resulting in severely low levels of protein in the blood. It is the most commonly occurring childhood chronic kidney disease. In Japan, it is both a designated intractable disease and a specific pediatric chronic disease. The cause has not been illuminated.It is a disease with unclear causes in which excessive amounts of protein are passed in the urine, resulting in severely low levels of protein in the blood. In Japan, it has been classified as both a specific pediatric chronic disease and a designated intractable disease. Between 80-90% of childhood nephrotic syndrome cases are steroid-sensitive nephrotic syndrome, meaning that they can be sent into complete remission through steroid treatment. However, about 20% of patients experience repeated relapses even in adulthood. There is a strong demand to illuminate the disease’s causes and pathology, and utilize this knowledge to develop a definitive treatment method.

The majority of steroid-sensitive nephrotic syndrome cases are multifactorial. It is thought to occur due to a combination of some kind of genetic factor (disease-susceptibility gene) and an immunological trigger, such as an infection.  An international research collaboration, including Professor Iijima Kazumoto of the Department of Pediatrics, Kobe University Graduate School of Medicine, has revealed that NPHS1 is a disease-susceptibility gene for steroid-sensitive nephrotic syndrome in children. Professor Iijima research up until now has revealed that HLA-DR/DQ is a disease-susceptibility gene, however susceptibility genes outside the HLA region have yet to be illuminated. The NPHS1 gene encodes nephrin, a component protein for the renal glomerulus slit diaphragm, which prevents protein from being passed in the urine. It is expected that these successful results will contribute towards understanding of the underlying mechanism and the development of new treatments for childhood nephrotic syndrome. The results of this study are published in the international scientific journal Kidney International on June 13.

A Genome-Wide Association Study (GWAS) was conducted to compare the Single Nucleotide Polymorphisms (SNPs) across all regions of the genome in Japanese patients with childhood steroid-sensitive nephrotic syndrome with those of healthy people. A trans-ethnic international meta-analysis was then conducted, and it revealed that NPHS1 is a disease-susceptibility gene. It is hoped that these findings will contribute towards illuminating the underlying mechanism behind childhood nephrotic syndrome and the development of new treatments. The research group has so far collected genomic DNA from around 1,300 patients with childhood nephrotic syndrome, with the cooperation of pediatric nephrology specialists across Japan. For this particular research, they used samples from 987 of the above cases that were childhood steroid-sensitive nephrotic syndrome with samples from 3,206 healthy Japanese donors as a control. GWAS was performed using the SNP array ‘Japonica’, which is the most appropriate for carrying out this genetic test on Japanese individuals.  From these results, variants in the NPHS1-KIRREL2 region on chromosome 19 (19q13.12) with genome-wide significance were identified. These variants are outside the HLA-DR/DQ region.

Trans-ethnic replication studies into these multiple variants in the NPHS1-KIRREL2 region were conducted across various populations, including Korean, South Asian, African, European, Hispanic and Maghrebian (Northwest African). The investigation covered patients with steroid-sensitive nephrotic syndrome (1,063 people in total) and healthy counterparts of the same ethnicity (19,729 people in total). The results were replicated in the Korean, South Asian and African datasets. An international meta-analysis including the Japanese cohort also illuminated the significance of these multiple variants in NPHS1. Subsequently, the relationship between these multiple variants in NPHS1 and NPHS1 mRNA expression in the glomerulus was investigated. The NPHS1 mRNA expression originating from chromosomes with haplotypes containing all the risk variants was low, revealing that these variants play a role in NPHS1 mRNA regulation. This research study revealed that NPHS1 is also a disease-susceptibility gene for steroid-sensitive nephrotic syndrome, the most commonly occurring multifactorial kidney disorder in children.  This research represents an important milestone in the understanding of the genetics behind steroid-sensitive nephrotic syndrome’s mechanism.

It will also bring about a paradigm shift in the field of nephrology. These results will contribute towards the development of new treatment methods as well. As a next step, scientists will investigate the link between HLA and nephrin. They aim to develop more effective, safe treatment and prevention methods for steroid-sensitive nephrotic syndrome while illuminating the causes and pathology behind the disease. Professor Iijuima has published also data about the effect of newest immunosuppressors (i.e. mycophenolate mofetil and rituximab) on the outcome of this steroid-sensitive kidney disease. He is oalso interested in finding other gene associations in other kidney diseases, like the autosomal distal tubular acidosis.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Jia X et al., Iijima K. Kidney Int. 2020 Jun 14:S0085-2538(20)30639-6. 

Sakuraya K, Nozu K, Oka I et al., Iijima K. CEN Case Rep. 2020 Jul 6. 

Nagano C et al., Iijima K. BMC Nephrol. 2019 Aug 2; 20(1):293. 

Horinouchi T et al., Iijima K. BMC Nephrol. 2018 Nov 1; 19(1):302. 

The following two tabs change content below.

Dott. Gianfrancesco Cormaci

Medico Chirurgo, Specialista; PhD. a CoFood s.r.l.
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento enzimaticamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (Leader of the R&D for the partnership CoFood s.r.l.) - Autore di articoli su informazione medica e salute sul sito www.medicomunicare.it (Medical/health information on website) - Autore di corsi ECM FAD pubblicizzati sul sito www.salutesicilia.it
- Advertisment -